top of page

Search

Exclusive: Pfizer’s CEO on Q2 earnings

blonca9
Aug 1, 2023
1 min read

Albert Bourla discusses Q2 earnings, FTC and Seagen, Pfizer’s capacity for more deals, GLP-1s, and provides an update on the NC tornado damage.

Recent Posts

After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor

After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor

Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year

Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year

Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June

Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page